Obstetrics and Gynaecology

Managing Inflammatory Bowel Disease in Pregnancy Safely

Published on Nov 18, 2026
2 min read
Managing Inflammatory Bowel Disease in Pregnancy Safely - OC Academy Medical Insights
"Learn key clinical guidance on inflammatory bowel disease in pregnancy, including medication safety, disease monitoring, and delivery planning strategies."

Managing inflammatory bowel disease in pregnancy requires vigilant clinical attention and multidisciplinary teamwork. Consequently, clinicians must balance maternal disease stability with fetal health. Active inflammation represents the greatest risk factor for adverse obstetric outcomes. Therefore, maintaining sustained disease remission serves as the primary management priority.

Managing Inflammatory Bowel Disease in Pregnancy

Preconception counseling allows physicians to optimize maternal nutrition and review surgical history. Furthermore, prior pelvic surgeries like ileal pouch-anal anastomosis can reduce fertility rates. However, assisted reproductive technologies offer comparable success rates for these patients. Clinicians should confirm endoscopic or biochemical remission before conception occurs. Moreover, routine monitoring with fecal calprotectin or intestinal ultrasound ensures early flare detection.

Medication Safety and Risk Stratification

Most maintenance therapies remain safe and essential throughout gestation. For example, aminosalicylates, thiopurines, and biologic agents prevent debilitating flares. Discontinuing these medications often triggers severe maternal disease reactivation. Consequently, doctors encourage women to continue biologics across all trimesters. In contrast, methotrexate causes significant teratogenic injury and remains strictly contraindicated. Additionally, clinicians avoid Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators due to safety concerns.

Delivery Planning and Multidisciplinary Care

Obstetric teams must individualize delivery planning through proactive multidisciplinary discussions. Specifically, active perianal Crohn disease warrants a planned cesarean delivery. A cesarean delivery also protects against sphincter trauma in rectovaginal fistula cases. However, women with inactive luminal disease can safely pursue vaginal delivery. Similarly, patients with an ileal pouch require shared decision-making regarding delivery route. Thus, coordinated care between gastroenterologists and obstetricians secures optimal maternal-fetal outcomes.

Frequently Asked Questions

Q1: Which medications are contraindicated during pregnancy in IBD?

Methotrexate is strictly contraindicated because of teratogenicity. Additionally, providers avoid Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators.

Q2: How does disease activity affect pregnancy outcomes?

Active inflammation significantly increases rates of preterm delivery and low birth weight. Therefore, maintaining stable remission is paramount.

Q3: When should a cesarean delivery be recommended for patients with IBD?

Surgeons recommend cesarean delivery for active perianal disease or rectovaginal fistulas. Furthermore, patients with an ileal pouch require individual assessment.

References

  1. Boyd T et al. Inflammatory Bowel Disease in Pregnancy. Obstet Gynecol. 2026 Nov 17. doi: 10.1097/AOG.0000000000006460. PMID: 43044085.
  2. Mahadevan U, Long MD, Kane SV, et al. Global Consensus Statement for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2025;169(4):789-804.
  3. Boyd T, Kane S. Update on Pregnancy in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2026;22(6):303-312.

Related Articles You May Like